Gyre Therapeutics ( (GYRE) ) has issued an announcement.
GNI Group Ltd., which has an indirect controlling interest in Gyre Therapeutics, Inc., reported its financial results for the fiscal year ending December 31, 2024. The company, involved in pharmaceuticals and clinical trials, experienced a decline in revenue and profits compared to 2023. Despite this, GNI anticipates significant developments in 2025, including Phase 3 trial results for Hydronidone in China and other clinical advancements. These upcoming milestones could potentially enhance GNI’s position in the pharmaceuticals market, particularly in liver disease treatment.
More about Gyre Therapeutics
YTD Price Performance: -0.17%
Average Trading Volume: 104,825
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.03B
See more data about GYRE stock on TipRanks’ Stock Analysis page.